However, rates of estimated ACR20, ACR50 and EULAR good response did show a numerical trend towards greater improvement in bDMARDs + MTX patients vs bDMARD monotherapy patients, consistent with prior research that demonstrated the superiority of bDMARD combination therapy over monotherapy [ 9 , 36 , 37 ].
← all excerpts
Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry.
1
—
—